Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dichlorphenamide for Periodic Paralysis
NCT00494507Phase 3Completed
- Sponsor
- University of Rochester
- Start
- Jun 2007
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of dichlorphenamide in hyperkalemic periodic paralysis (HyperKPP) and hypokalemic periodic paralysis (HypoPP) (4 arms), sponsored by University of Rochester. Primary endpoint: HYP/HOP Attack Rate at 8 weeks. Started Jun 2007; status: completed.
02
Drugs
dichlorphenamide
03
Conditions
hyperkalemic periodic paralysis (HyperKPP)hypokalemic periodic paralysis (HypoPP)
Beyond the preview
Go deeper on NCT00494507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494507.